Acitretin Plasma Levels Under Hemodialysis
Information source: University of Zurich
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Carcinoma, Squamous Cell
Intervention: Chemopreventive application (Acitretin) (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: University of Zurich Official(s) and/or principal investigator(s):
01 Studienregister MasterAdmins, Study Director, Affiliation: UniversitaetsSpital Zuerich
Overall contact:
01 Studienregister MasterAdmins, Phone: +41 (0)44 255 11 11
Summary
Acitretin is given to hemodialysis patients who have developed in-situ or invasive squamous
cell carcinoma of the skin in increasing doses up to 25 mg daily for one year.
Clinical Details
Official title: Acitretin Plasma Levels Under Hemodialysis
Study design: Prevention, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Pharmacokinetics/Dynamics Study
Primary outcome: Plasma levels acitretin
Detailed description:
Acitretin is given to hemodialysis patients who have developed in-situ or invasive squamous
cell carcinoma of the skin in increasing doses up to 25 mg daily for one year. Plasma levels
of acitretin will be monitored and influence of hemodialysis on acitretin plasma levels will
be determined. Number of in-situ or invasive squamous cell carcinoma of the skin cases will
be determined.
- Trial with medicinal product
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion criteria:
- Hemodialyis patients with at least one case of in-situ or invasive squamous cell
carcinoma of the skin
Exclusion criteria:
- Hepatopathy
- Pregnancy
Locations and Contacts
01 Studienregister MasterAdmins, Phone: +41 (0)44 255 11 11
Clinic for Dermatology University Hospital of Zurich, Zurich, Switzerland; Recruiting
Günther Hofbauer, MD, Email: hofbauer@usz.ch
günther Hofbauer, MD, Principal Investigator
Additional Information
Starting date: June 2007
Ending date: June 2011
Last updated: June 5, 2008
|
